Ann: Appendix 4E & Preliminary Final Report, page-88

From the last quarterly announcement:

"PharmAust, together with the Walter and Eliza Hall Institute, are conducting a comparative analysis on human pulmonary epithelial cells with MPL and other mTOR inhibitors, such as rapamycin and current anti-viral drugs authorised by the FDA for emergency use to treat COVID-19, such as remdesivir. Once these assays are received, PharmAust will prepare an Executive Summary and an Investigator's Brochure to permit discussions with clinicians about a Phase I trial in a small number of human patients to treat COVID-19.Monepantel has already been evaluated in human patients with cancer (ASX announcement 21 October 2015),so human safety data is already available to facilitate the next steps."

It's clear from yesterday's financial year announcement and the announcement before that that work is far from complete. Not like you to forget such an essential detail is it Buckland